These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36042198)

  • 41. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.
    Erdem HA; Korkma PE; Çağlayan D; Işıkgöz Taşbakan M; Yamazhan T; Taşbakan MS; Sayıner A; Gökengin D
    Turk J Med Sci; 2021 Jun; 51(3):912-920. PubMed ID: 33237663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
    Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
    Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
    Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM
    Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
    Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
    Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
    Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
    Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach.
    Abdel-Halim H; Hajar M; Hasouneh L; Abdelmalek SMA
    Drug Des Devel Ther; 2022; 16():2995-3013. PubMed ID: 36110398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies.
    Soto-Acosta R; Edwards TC; Dreis CD; Krishna VD; Cheeran MC; Qiu L; Xie J; Bonnac LF; Geraghty RJ
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.
    Baz M; Goyette N; Griffin BD; Kobinger GP; Boivin G
    Antivir Ther; 2017; 22(7):613-618. PubMed ID: 28694390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
    Manabe T; Kambayashi D; Akatsu H; Kudo K
    BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
    Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
    Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
    Papp H; Lanszki Z; Keserű GM; Jakab F
    Geroscience; 2022 Jun; 44(3):1263-1268. PubMed ID: 35543795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positive-strand RNA viruses-a Keystone Symposia report.
    Cable J; Denison MR; Kielian M; Jackson WT; Bartenschlager R; Ahola T; Mukhopadhyay S; Fremont DH; Kuhn RJ; Shannon A; Frazier MN; Yuen KY; Coyne CB; Wolthers KC; Ming GL; Guenther CS; Moshiri J; Best SM; Schoggins JW; Jurado KA; Ebel GD; Schäfer A; Ng LFP; Kikkert M; Sette A; Harris E; Wing PAC; Eggenberger J; Krishnamurthy SR; Mah MG; Meganck RM; Chung D; Maurer-Stroh S; Andino R; Korber B; Perlman S; Shi PY; Bárcena M; Aicher SM; Vu MN; Kenney DJ; Lindenbach BD; Nishida Y; Rénia L; Williams EP
    Ann N Y Acad Sci; 2023 Mar; 1521(1):46-66. PubMed ID: 36697369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.
    Yamazaki S; Suzuki T; Sayama M; Nakada TA; Igari H; Ishii I
    J Infect Chemother; 2021 Feb; 27(2):390-392. PubMed ID: 33402301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
    Pertinez H; Rajoli RKR; Khoo SH; Owen A
    J Antimicrob Chemother; 2021 Jul; 76(8):2121-2128. PubMed ID: 34075418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
    Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T
    J Infect Chemother; 2021 Sep; 27(9):1350-1356. PubMed ID: 34176716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
    Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
    Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.